- Home
- ME vs ACHV Comparison
ME vs ACHV Comparison
Compare ME & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- ACHV
- Stock Information
- Founded
- ME 2006
- ACHV N/A
- Country
- ME United States
- ACHV Canada
- Employees
- ME N/A
- ACHV N/A
- Industry
- ME Precision Instruments
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ME Health Care
- ACHV Health Care
- Exchange
- ME Nasdaq
- ACHV Nasdaq
- Market Cap
- ME 168.9M
- ACHV 159.0M
- IPO Year
- ME N/A
- ACHV N/A
- Fundamental
- Price
- ME $0.34
- ACHV $4.52
- Analyst Decision
- ME Hold
- ACHV Strong Buy
- Analyst Count
- ME 1
- ACHV 3
- Target Price
- ME $0.47
- ACHV $14.00
- AVG Volume (30 Days)
- ME 2.3M
- ACHV 85.7K
- Earning Date
- ME 11-06-2024
- ACHV 11-07-2024
- Dividend Yield
- ME N/A
- ACHV N/A
- EPS Growth
- ME N/A
- ACHV N/A
- EPS
- ME N/A
- ACHV N/A
- Revenue
- ME $199,188,000.00
- ACHV N/A
- Revenue This Year
- ME $0.05
- ACHV N/A
- Revenue Next Year
- ME $17.98
- ACHV N/A
- P/E Ratio
- ME N/A
- ACHV N/A
- Revenue Growth
- ME N/A
- ACHV N/A
- 52 Week Low
- ME $0.29
- ACHV $3.03
- 52 Week High
- ME $1.13
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- ME 51.25
- ACHV 50.71
- Support Level
- ME $0.29
- ACHV $4.23
- Resistance Level
- ME $0.32
- ACHV $4.33
- Average True Range (ATR)
- ME 0.02
- ACHV 0.15
- MACD
- ME 0.01
- ACHV 0.02
- Stochastic Oscillator
- ME 98.57
- ACHV 53.13
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.